Document is current
Any future updates will be listed below
-
Authors
Nikulin, Pavel https://orcid.org/0000-0002-4568-4018
Hoberück, Sebastian
Apostolova, Ivayla
Maus, Jens
Hüttmann, Andreas
Dührsen, Ulrich
Kroschinsky, Frank
Kotzerke, Jörg
von Bonin, Malte
Bundschuh, Ralph A.
Braune, Anja
Hofheinz, Frank
-
Funding
Funding for this research was provided by:
Helmholtz-Zentrum Dresden - Rossendorf e.V.
- License Information
-
More Information
Article History
Received: 11 November 2025
Accepted: 3 February 2026
First Online: 24 March 2026
Declarations
:
: RAB is Consultant for and has received speaker’s honoraria from Bayer Healthcare (Leverkusen, Germany), Novartis (Nürnberg, Germany), Terumo GmbH (Eschborn, Germany), and Eisai GmbH (Frankfurt, Germany) and has received travel expenses from Blue Earth Therapeutics (Oxford, UK). SH is consultant for Novartis (Nürnberg, Germany).
: The PETAL trial was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Duisburg-Essen (July 25, 2007; no. 07–3366). Retrospective analysis was conducted in accordance with the guidelines of the International Conference on Harmonization/Good Clinical Practice and the principles of the Declaration of Helsinki.
: All patients provided written informed consent.
: Not applicable.
